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neBACKGROUND The incidence of pneumonia and subsequent outcomes has not been compared in patients with heart
failure and reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF).
OBJECTIVES This study aimed to examine the rate and impact of pneumonia in the PARADIGM-HF (Prospective
Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin Converting Enzyme Inhibitor to Determine
Impact on Global Mortality and Morbidity in Heart Failure) and PARAGON-HF (Prospective Comparison of ARNI with ARB
Global Outcomes in Heart Failure with Preserved Ejection Fraction) trials.
METHODS The authors analyzed the incidence of investigator-reported pneumonia and the rates of HF hospitalization,
cardiovascular death, and all-cause death before and after the occurrence of pneumonia, and estimated risk after the first
occurrence of pneumonia in unadjusted and adjusted analyses (the latter including N-terminal pro–B-type natriuretic
peptide).
RESULTS In PARADIGM-HF, 528 patients (6.3%) developed pneumonia after randomization, giving an incidence rate of
29 (95% CI: 27 to 32) per 1,000 patient-years. In PARAGON-HF, 510 patients (10.6%) developed pneumonia, giving an
incidence rate of 39 (95% CI: 36 to 42) per 1,000 patient-years. The subsequent risk of all trial outcomes was elevated
after the occurrence of pneumonia. In PARADIGM-HF, the adjusted hazard ratio (HR) for the risk of death from any cause
was 4.34 (95% CI: 3.73 to 5.05). The corresponding adjusted HR in PARAGON-HF was 3.76 (95% CI: 3.09 to 4.58).
CONCLUSIONS The incidence of pneumonia was high in patients with HF, especially HFpEF, at around 3 times the
expected rate. A first episode of pneumonia was associated with 4-fold higher mortality. (Prospective Comparison of
Angiotensin Receptor–Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global
Mortality and Morbidity in Heart Failure [PARADIGM-HF], NCT01035255; Prospective Comparison of ARNI [Angiotensin
Receptor–Neprilysin Inhibitor] With ARB [Angiotensin Receptor Blocker] Global Outcomes in Heart Failure With Preserved
Ejection Fraction [PARAGON-HF], NCT01920711) (J Am Coll Cardiol 2021;77:1961–73) © 2021 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2021.03.001
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eGFR = estimated glomerular
filtration rate
HF = heart failure
HFpEF = heart failure and
preserved ejection fraction
HFrEF = heart failure and
reduced ejection fraction
KCCQ-CSS = Kansas City
Cardiomyopathy Questionnaire
clinical summary score
LVEF = left ventricular ejection
fraction
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
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1962I n the United States, community-acquired pneumonia affects >5 millionadults and is associated with approxi-
mately 1.5 million hospital admissions and
up to 100,000 deaths annually (1–3). In the
United Kingdom, pneumonia accounts for
more hospital admissions and bed-days
than any other lung condition, and world-
wide, pneumonia is a significant cause of
morbidity and mortality, especially in the
elderly (4). Indeed, the aging of many popu-
lations is thought to be one reason why hos-
pitalizations for pneumonia have increased
by up to 50% in Western countries over the
past 2 decades and survival from pneumonia
has changed little in half a century (5,6).
Although usually considered to be an acute
event, there is evidence that pneumonia isassociated with long-term cardiovascular sequelae,
particularly acute coronary events, and the same
may be true for heart failure (HF), although this has
not been investigated fully (1).SEE PAGE 1974Patients with HF are thought to be at 2-fold higher
risk of pneumonia than age- and sex-matched in-
dividuals in the population, and survival from pneu-
monia is lower in patients with HF than in those
without. Conversely, pneumonia increases the risk of
worsening HF and is often considered a factor in
decompensation leading to hospitalization (7–9). The
most common cause of pneumonia is infection with
the bacterium Streptococcus pneumoniae (10,11). Two
pneumococcal vaccines are available and recom-
mended in patients with HF. Influenza also causes
pneumonia, and vaccination against influenza is
widely available and inexpensive (12). However, up-
take of each of these vaccines is poor and may even be
declining (13). This deficiency in care may be partic-
ularly problematic for patients with HF and preserved
ejection fraction (HFpEF), who have fewer other
treatment options, compared with patients with HF
and reduced ejection fraction (HFrEF) (14–16)., University Medical Center Groningen, University of Groningen, G
lurithématique 1433 and Institut National de la Santé et de la Re
re, French Clinical Research Infrastructure Network, Investigation
ancy, France; mRalph H. Johnson Department of Veterans Affa
of South Carolina, Charleston, South Carolina, USA; and the nBa
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s attest they are in compliance with human studies committe
and Food and Drug Administration guidelines, including patien
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received January 11, 2021; revised manuscript received March 1,In the present post hoc analysis, we examined the
incidence of pneumonia in the PARADIGM-HF (Pro-
spective Comparison of Angiotensin Receptor–
Neprilysin Inhibitor With Angiotensin Converting
Enzyme Inhibitor to Determine Impact on Global
Mortality and Morbidity in Heart Failure) trial, which
enrolled a large cohort of ambulatory HFrEF patients
with predominantly mild symptoms who were
receiving contemporary therapy, and compared this
with the incidence of pneumonia in patients with
HFpEF in the PARAGON-HF (Prospective Comparison
of ARNI [Angiotensin Receptor–Neprilysin Inhibitor]
with ARB [Angiotensin Receptor Blocker] Global
Outcomes in Heart Failure with Preserved Ejection
Fraction) trial (17–22). We also examined outcomes
after pneumonia to assess the longer-term sequelae
of this respiratory infection.METHODS
STUDY POPULATION. This study consisted of 8,399
patients with HFrEF randomized in PARADIGM-HF
and 4,796 patients with HFpEF in PARAGON-HF.
The design, baseline characteristics, and results of
PARADIGM-HF and PARAGON-HF have been pub-
lished (17–22). Each was a randomized, double-blind,
controlled trial that compared sacubitril/valsartan
with a renin-angiotensin system blocker alone. Each
trial enrolled adults ($18 years of age in PARADIGM-
HF and $50 years of age in PARAGON-HF) with
symptomatic HF, defined as New York Heart Associ-
ation (NYHA) functional class II to IV. Patients also
needed to have functional or structural cardiac dis-
ease and elevated natriuretic peptides. In
PARADIGM-HF, patients were required to have left
ventricular ejection fraction (LVEF) #40% and in
PARAGON-HF LVEF $45% and left ventricular hy-
pertrophy, left atrial enlargement, or both. In both
trials, patients were also required to have an elevated
B-type natriuretic peptide (BNP) or N-terminal pro-
BNP (NT-proBNP) level (with different thresholds
depending on the occurrence of recent HF hospitali-
zation and presence of atrial fibrillation/flutter).roningen, the Netherlands; lCentre d’Investigations
cherche Médicale U1116, Centre Hospitalier Regional
Network Initiative Cardiovascular and Renal Clinical
irs Medical Center, Division of Cardiology, Medical
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1963In each trial, patients entered an initial run-in
period during which they received the comparator
(enalapril or valsartan), followed by a second period
of treatment with sacubitril/valsartan. Patients
tolerating both run-in periods were randomized 1:1
to sacubitril/valsartan (target dose 97/103 mg twice
daily) and either enalapril (target dose 10 mg twice
daily) in PARADIGM-HF or valsartan (target dose
160 mg twice daily) in PARAGON-HF. Each trial was
approved by ethics committees at the investigative
sites, and all patients provided written informed
consent. Each trial was event driven, and the median
follow-up in PARADIGM-HF was 27 months (stopped
early for efficacy) and in PARAGON-HF was
35 months (completed follow-up to targeted number
of events).
CASES OF PNEUMONIA. Cases of pneumonia during
follow-up were identified from investigator-reported
adverse events recorded in the case report form and
coded according to the Medical Dictionary for Regu-
latory Activities. Any event with the coding “pneu-
monia” was included in this analysis except
aspiration pneumonia, whether a specific pathogen
was named or not and regardless of any
named pathogen.
COMPARATOR GROUP. To determine whether infec-
tion per se identified patients at high risk (“vulner-
able” patients) or increased subsequent risk, we used
a comparator group with another type of infection.
The only other group of sufficient size for analysis
was urinary tract infection.
OUTCOMES. In PARADIGM-HF, the primary endpoint
was time to first occurrence of HF hospitalization
or cardiovascular death, and in PARAGON-HF the
primary outcome was all HF hospitalizations
(including first and repeated admissions) or cardio-
vascular death. In the present analysis, the primary
outcome used for both trials was time to first occur-
rence of HF hospitalization or cardiovascular death.
We also examined the components of the primary
end point and death from any cause. All events
in the 2 trials were adjudicated by the same
endpoints committee.
STATISTICAL ANALYSIS. Baseline characteristics of
patients who did and did not develop incident
pneumonia are presented as mean  SD or median
(interquartile range) for continuous variables and n
(%) for categoric variables. The baseline characteris-
tics of patients who did and did not develop pneu-
monia during follow-up were compared by means of
the Student’s t-test or Mann-Whitney U test asappropriate for continuous variables and the chi-
square test for categoric variables.
Incident rates for pneumonia during follow-up
were calculated with the use of Kaplan-Meier esti-
mates as 1,000 patient-years of follow-up. The ef-
fect of randomized treatment on the occurrence of
pneumonia was estimated with the use of Cox
proportional hazards models, with geographic re-
gion as a stratification factor. To describe the
prognosis of patients who experienced an incidence
of pneumonia on subsequent outcomes of interest,
the time to event from the date of pneumonia
occurrence to the date of the outcome of interest or
end of follow-up (whichever occurred first) was
used to estimate the incidence rate and cumulative
incidence risk according to Kaplan-Meier estimates.
Among individuals who experienced >1 episode of
pneumonia, the first episode was considered as the
index event. To estimate the incidence rate of
outcomes that occurred from randomization to the
occurrence of pneumonia or end of follow-up
(whichever occurred first), the time to event from
the date of randomization to the date of the
outcome of interest was used. For individuals who
experienced pneumonia events, only those events
that occurred before the incidence of pneumonia
were considered; otherwise, they were censored at
the day of pneumonia occurrence. Individuals
without the event of interest and who did not
experience an incidence pneumonia were censored
at the end of follow-up.
The association between incidence of pneumonia
and subsequent risks of clinical outcomes was
examined with pneumonia as a time-updated vari-
able in a Cox regression analysis that considered the
time before the onset of pneumonia and the time
from the onset of pneumonia to the occurrence of
clinical outcomes, with stratification by region (23).
The association was further adjusted for treatment
assignment and baseline covariates, including age,
sex, LVEF, NYHA functional class, systolic blood
pressure, HF duration, previous HF hospitalization,
history of myocardial infarction, hypertension, dia-
betes, and atrial fibrillation, estimated glomerular
filtration rate (eGFR), and NT-proBNP. We conducted
3 sensitivity analyses related to the trial outcomes in
patients with pneumonia: The first excluded patients
with an episode of pneumonia which coincided with a
HF hospitalization, the second excluded patients who
died during the episode of pneumonia and the third
excluded patients who died during an episode of
pneumonia or within the 4 weeks after such an event,













(n ¼ 510) p Value
Age, yrs 63.6  11.4 66.9  11.6 <0.0001 72.4  8.4 75.6  8.0 <0.0001
Male 6,124 (77.8) 443 (83.9) 0.001 2,056 (48.0) 261 (51.2) 0.1707
Race 0.528 0.0679
White 5,182 (65.8) 362 (68.6) 3,510 (81.9) 397 (77.8)
Black 404 (5.1) 24 (4.5) 86 (2.0) 16 (3.1)
Asian 1,425 (18.1) 84 (15.9) 536 (12.5) 71 (13.9)
Other 860 (10.9) 58 (11.0) 154 (3.6) 26 (5.1)
Region <0.0001 <0.0001
North America 529 (6.7) 73 (13.8) 444 (10.4) 115 (22.5)
Latin America 1,336 (17.0) 97 (18.4) 321 (7.5) 49 (9.6)
Western Europe and other* 1,899 (24.1) 152 (28.8) 1,372 (32.0) 171 (33.5)
Central Europe 2,702 (34.3) 124 (23.5) 1,612 (37.6) 103 (20.2)
Asia-Pacific 1,405 (17.9) 82 (15.5) 537 (12.5) 72 (14.1)
Body mass index, kg/m2 28.2  5.5 27.9  5.7 0.2366 30.2  5.0 30.1  5.1 0.4779
Systolic blood pressure, mm Hg 121.4  15.2 121.7  16.8 0.6438 130.7  15.2 129.2  17.5 0.0432
Diastolic blood pressure, mm Hg 73.7  10.0 72.2  10.9 0.0015 74.6  10.4 72.0  11.3 <0.0001
Heart rate, beats/min 72.3  11.9 72.7  13.2 0.4456 70.5  12.3 70.1  12.2 0.5727
Left ventricular ejection fraction, % 29.5  6.2 29.3  6.6 0.4866 57.5  7.9 57.7  8.1 0.6733
NYHA functional class 0.9545 0.0046
I 362 (4.6) 27 (5.1) 119 (2.8) 18 (3.5)
II 5550 (70.6) 369 (70.2) 3343 (78.0) 363 (71.3)
III 1892 (24.1) 126 (24.0) 805 (18.8) 127 (25.0)
IV 56 (0.7) 4 (0.8) 18 (0.4) 1 (0.2)
Ischemic etiology of HF 4703 (59.8) 333 (63.1) 0.1321 1535 (35.8) 188 (36.9) 0.6435
Heart failure duration <0.0001 0.5688
Within 1 yr 2,408 (30.6) 115 (21.8) 1,773 (41.5) 202 (39.8)
>1–5 yrs 3,026 (38.4) 206 (39.0) 1,496 (35.0) 176 (34.6)
>5 yrs 2,437 (31.0) 207 (39.2) 1,007 (23.6) 130 (25.6)
Current smoking 1,129 (14.3) 79 (15.0) 0.6951 316 (7.4) 37 (7.3) 0.9129
Alcohol use† 0.0319 0.8205
<1 drink per day 6,968 (88.5) 448 (84.8) 2,751 (84.5) 339 (85.0)
1–2 drinks per day 733 (9.3) 67 (12.7) 432 (13.3) 53 (13.3)
$3 drinks per day 170 (2.2) 13 (2.5) 73 (2.2) 7 (1.8)
Continued on the next page
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1964and in the third we examined the risk associated with
pneumonia according to the time interval after an
episode of this infection: #1 month, >1 month to
3 months, and >3 months.
A 2-sided p value of <0.05 was considered to be
statistically significant. All analyses were performed
with the use of Stata version 15 (Statacorp, College
Station, Texas).
RESULTS
In PARADIGM-HF, 528 patients (6.3%) developed
pneumonia after randomization, giving an incidence
rate of 29 (95% CI: 27 to 32) per 1,000 patient-years. In
PARAGON-HF, 510 patients (10.6%) developedpneumonia, giving an incidence rate of 39 (95% CI: 36
to 42) per 1,000 patient-years.
BASELINE CHARACTERISTICS. PARADIGM-HF. Table 1
summarizes the baseline characteristics of patients
who did and did not develop pneumonia during
follow-up. Patients with pneumonia, compared with
those without, were older (66.9 years vs. 63.6 years;
p < 0.001) and were more likely to be male (83.9% vs.
77.8%; p < 0.001). Participants developing pneu-
monia also had HF for longer, but there was no dif-
ference in the frequency of previous HF
hospitalization. They also had a lower (worse) Kansas
City Cardiomyopathy Questionnaire clinical summary
score (KCCQ-CSS) than patients not developing














(n ¼ 510) p Value
Medical history
Hospitalization for heart failure 4,927 (62.6) 347 (65.7) 0.1507 2,027 (47.3) 279 (54.7) 0.0015
Myocardial infarction 3,387 (43.0) 247 (46.8) 0.0923 969 (22.6) 114 (22.4) 0.8962
Angina 2,151 (27.3) 153 (29.0) 0.411 1,235 (28.8) 153 (30.0) 0.5769
CABG or PCI 2,429 (30.9) 211 (40.0) <0.0001 1,153 (26.9) 168 (32.9) 0.0039
Hypertension 5,544 (70.4) 396 (75.0) 0.0257 4,093 (95.5) 491 (96.3) 0.4193
Diabetes 2,682 (34.1) 225 (42.6) <0.0001 1,814 (42.3) 248 (48.6) 0.0066
Atrial fibrillation 2,850 (36.2) 241 (45.6) <0.0001 2,208 (51.5) 313 (61.4) <0.0001
Atrial fibrillation or flutter on ECG 1,948 (24.7) 142 (26.9) 0.2698 1,361 (31.8) 191 (37.5) 0.0093
Stroke 665 (8.4) 60 (11.4) 0.021 442 (10.3) 66 (13.0) 0.0632
COPD 945 (12.0) 135 (25.6) <0.0001 537 (12.5) 133 (26.2) <0.0001
Asthma 288 (3.7) 26 (4.9) 0.1379 288 (6.7) 60 (11.8) <0.0001
Influenza vaccination 1,591 (20.2) 178 (33.7) <0.0001 1,439 (33.7) 254 (50.1) <0.0001
Treatment
Digoxin 2,386 (30.3) 153 (29.0) 0.5174 408 (9.5) 42 (8.2) 0.3471
Diuretics 6,303 (80.1) 435 (82.4) 0.1975 4,093 (95.5) 492 (96.5) 0.3108
Pretrial use of ACE inhibitors or ARBs 7,853 (99.8) 526 (99.6) 0.4933 3,723 (86.9) 416 (81.6) 0.001
Randomized treatment‡ 3,923 (49.8) 264 (50.0) 0.9437 2,154 (50.3) 253 (49.6) 0.7818
Beta-blockers 7,331 (93.1) 480 (90.9) 0.0519 3,424 (79.9) 397 (77.8) 0.278
Aldosterone antagonists 4,427 (56.2) 244 (46.2) <0.0001 1,115 (26.0) 124 (24.3) 0.4067
Antiplatelets 4,416 (56.1) 320 (60.6) 0.0435 1,953 (45.6) 241 (47.3) 0.4695
Anticoagulants 2,488 (31.6) 197 (37.3) 0.0065 1,366 (31.9) 185 (36.3) 0.0445
Statins 4,403 (55.9) 320 (60.6) 0.0364 2,728 (63.6) 327 (64.1) 0.8352
Pacemaker 985 (12.5) 103 (19.5) <0.0001 400 (9.3) 59 (11.6) 0.1047
Implantable cardioverter-defibrillator 1,130 (14.4) 113 (21.4) <0.0001 16 (0.4) 2 (0.4) 0.9475
Cardiac resynchronization therapy 517 (6.6) 57 (10.8) 0.0002 – – –
Symptoms, signs, and HRQL
Dyspnea on effort 6,769 (86.2) 438 (83.3) 0.0653 3,963 (92.6) 461 (90.7) 0.143
Dyspnea at rest 280 (3.6) 29 (5.5) 0.0216 127 (3.0) 12 (2.4) 0.443
Orthopnea 559 (7.1) 49 (9.3) 0.0597 767 (17.9) 119 (23.4) 0.0025
Paroxysmal nocturnal dyspnea 366 (4.7) 33 (6.3) 0.0922 162 (3.8) 29 (5.7) 0.0361
Rales 1,635 (20.8) 113 (21.5) 0.7128 293 (6.8) 52 (10.2) 0.0052
Edema 763 (9.7) 55 (10.5) 0.5778 1,608 (37.6) 218 (42.9) 0.0187
Jugular venous distention 618 (7.9) 45 (8.6) 0.5705 564 (13.3) 91 (18.1) 0.0031
Third heart sound 756 (9.6) 40 (7.6) 0.1259 101 (2.4) 10 (2.0) 0.5821
Fatigue 4,098 (52.2) 245 (46.6) 0.0131 2,202 (51.4) 235 (46.4) 0.0303
KCCQ clinical summary score§ 80 (64–92) 76 (62–89) 0.0002 75 (61- 87) 71 (54–84) <0.0001
Laboratory measures
Creatinine, mg/dl 1.12  0.30 1.21  0.30 <0.0001 1.08  0.31 1.15  0.31 <0.0001
eGFR, ml/min/1.73 m2 68.1  20.2 61.9  17.7 <0.0001 63.0  19.2 58.7  17.8 <0.0001
eGFR <60 ml/min/1.73 m2 2796 (35.5) 265 (50.2) <0.0001 2048 (47.8) 293 (57.5) <0.0001
Hemoglobin, g/l 139.4  15.9 139.7  17.7 0.6825 135.4  15.4 131.9  15.8 <0.0001
Albumin, g/l 42.8  3.1 42.1  3.3 <0.0001 42.3  3.0 41.6  3.3 <0.0001
Hematocrit, % 42.3  4.8 42.4  5.3 0.864 43.1  4.7 42.3  5.0 0.0005
NT-proBNP, pg/ml 1,585 (877-3,118) 2,142 (1,094–4,326) <0.0001 895 (458–1,583) 1,017 (546–1,821) 0.0003
No atrial fibrillation or flutter on ECG 1,465 (812–2,935) 2,078 (1,015–4,367) 591 (377-1,045) 669 (425–1,165)
Atrial fibrillation or flutter on ECG 1,976 (1,154–3,848) 2,466 (1,307–4,093) 1,568 (1,161–2,239) 1,722 (1,231–2,530)
Values are mean  SD, n (%), or median (interquartile range). *This category includes South Africa and Israel. †One drink equals 12 ounces of beer, 8 ounces of malt liquor, 5 ounces of wine, or
1.5 ounces or a “shot” of 80-proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey). ‡Treatment was sacubitril/valsartan vs. enalapril in PARADIGM-HF, and sacubitril/valsartan vs.
valsartan in PARAGON-HF. §Range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations associated with heart failure.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CABG ¼ coronary artery bypass grafting; COPD ¼ chronic obstructive pulmonary disease;
ECG ¼ electrocardiography; eGFR ¼ estimated glomerular filtration rate; HF ¼ heart failure; HRQL ¼ health-related quality of life; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; NT-
proBNP ¼ N-terminal pro-B-type natriuretic peptide; NYHA ¼ New York Heart Association; PARADIGM-HF ¼ Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor With
Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart failure trial; PARAGON-HF ¼ Prospective Comparison of ARNI With ARB Global
Outcomes in Heart Failure With Preserved Ejection Fraction trial; PCI ¼ percutaneous coronary intervention.
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Years After Incident Pneumonia
11.3



































Before Incident Pneumonia After Incident Pneumonia
The line graphs show the cumulative incidence risks of (A) the composite of the first HF hospitalization or CV death, (B) CV death, (C) the first HF hospitalization, and
(D) all-cause death after the occurrence of pneumonia. (E) The bar graph shows the incidence rates (per 100 patient-years) for the composite outcome of the first HF
hospitalization or CV death, CV death, HF hospitalization, and all-cause death. The blue bars are the rates before the occurrence of pneumonia, and the red bars are the
rates after the occurrence of pneumonia. CV ¼ cardiovascular; HF ¼ heart failure.
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3.65 (2.79 to 4.79)
3.03 (2.31 to 3.98)
2.19 (1.70 to 2.84)
1.98 (1.52 to 2.58)
2.45 (1.97 to 3.05)
2.22 (1.77 to 2.77)
Shen, L. et al. J Am Coll Cardiol. 2021;77(16):1961–73.
(A) The cumulative incidence of death from any cause in PARADIGM-HF and in PARAGON-HF and (included as insets) the incidence rates (per 100 patient-years) for
all-cause death before and after incident pneumonia in PARADIGM-HF and in PARAGON-HF. (B) The subsequent risk of clinical outcomes after incident pneumonia in
PARADIGM-HF and in PARAGON-HF. The composite outcome is the first occurrence of HF hospitalization or CV death. CI ¼ confidence interval; CV ¼ cardiovascular;
HF ¼ heart failure; HFrEF ¼ heart failure and reduced ejection fraction; HFpEF ¼ heart failure and preserved ejection fraction; HR ¼ hazard ratio; PARADIGM-
HF ¼ Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality
and Morbidity in Heart failure trial; PARAGON-HF ¼ Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction trial.
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1967difference in NYHA functional class. In general, pa-
tients who developed pneumonia had more symp-
toms and signs of HF than those who did not
develop pneumonia. Patients with pneumonia also
had more comorbidity, including chronic obstructivepulmonary disease (25.6% vs. 12.0%), diabetes (42.6%
vs. 34.1%), and atrial fibrillation (45.6% vs. 36.2%).
They also had a higher NT-proBNP level and a lower
eGFR than patients who did not develop pneu-
monia (Table 1).
TABLE 2 Subsequent Risk of Clinical Outcomes After Occurrence of Pneumonia in
PARADIGM-HF and PARAGON-HF
Unadjusted
HR* (95% CI) p Value
Adjusted
HR*† (95% CI) p Value
PARADIGM-HF
All-cause death 5.19 (4.47–6.03) <0.001 4.34 (3.73–5.05) <0.001
CV death 4.40 (3.68–5.26) <0.001 3.62 (3.02–4.34) <0.001
HF hospitalization 2.95 (2.30–3.78) <0.001 2.39 (1.86–3.07) <0.001
CV death or HF hospitalization 3.34 (2.79–3.99) <0.001 2.72 (2.27–3.26) <0.001
PARAGON-HF
All-cause death 4.53 (3.73–5.50) <0.001 3.76 (3.09–4.58) <0.001
CV death 3.65 (2.79–4.79) <0.001 3.03 (2.31–3.98) <0.001
HF hospitalization 2.19 (1.70–2.84) <0.001 1.98 (1.52–2.58) <0.001
CV death or HF hospitalization 2.45 (1.97–3.05) <0.001 2.22 (1.77–2.77) <0.001
*Hazard ratios were estimated with stratification by geographic region. †Adjusted variables included randomized
treatment, age, sex, left ventricular ejection fraction, NYHA functional class, systolic blood pressure, HF duration,
previous HF hospitalization, history of myocardial infarction, hypertension, diabetes, and atrial fibrillation, eGFR,
and log-transformed NT-proBNP.
CI ¼ confidence interval; CV ¼ cardiovascular; HF ¼ heart failure; HR ¼ hazard ratio; other abbreviations as in
Table 1.
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1968PARAGON-HF. The differences in baseline charac-
teristics between patients who did and did not develop
pneumonia during follow-up were broadly similar in
PARAGON-HF to the differences observed in
PARADIGM-HF and are also presented in Table 1. Pa-
tients with pneumonia, compared with those without,
also were older (75.6 years vs. 72.4 years; p < 0.001)
andmore likely to bemale, although the sex difference
was not significant in PARAGON-HF (51.2% vs. 48.0%;
p ¼ 0.171). Participants developing pneumonia had a
higher frequency of previous HF hospitalization, but
there was no difference in the duration of HF. They
also had a lower KCCQ-CSS (71 vs. 75) and worse NYHA
functional class than patients not developing pneu-
monia. Patients who developed pneumonia had more
symptoms and signs of HF than those who did not
develop pneumonia, and the differences were more
pronounced than in PARADIGM-HF. Patients with
pneumonia also had more comorbidity, including
chronic obstructive pulmonary disease (26.2% vs.
12.5%), diabetes (48.6% vs. 42.3%), and atrial fibrilla-
tion (61.4% vs. 51.5%). They had also a higher NT-
proBNP level and a lower eGFR than patients who
did not develop pneumonia (Table 1).
Smoking. Of note, there was no difference in the rate
of current smoking between those developing or not
developing pneumonia in either trial.
FATAL AND NONFATAL HF OUTCOMES AFTER
OCCURRENCE OF PNEUMONIA. PARADIGM-HF. The
cumulative probabilities of the composite primary
outcome, death from cardiovascular causes,hospitalization for HF, and death from any cause after
the occurrence of pneumonia are shown in Figure 1.
The incidence rates for these outcomes before and
after the occurrence of pneumonia are also compared
in Figure 1. A first occurrence of pneumonia was asso-
ciated with a 3- to 5-fold elevation in risk of subse-
quent outcomes, which remained significant after
extensive adjustment for other prognostic variables
(Central Illustration, Table 2). Notably, the rate for
death from any cause was 7.4 per 100 patient-years
before the occurrence of pneumonia and 39.5 per 100
patient-years after the occurrence of pneumonia,
representing a more than 4-fold elevation in risk of
death from any cause (adjusted HR: 4.34; 95% CI: 3.73
to 5.05).
PARAGON-HF. For all outcomes of interest, the inci-
dence rates before and after the occurrence of pneu-
monia are shown in Figure 2. The subsequent risks of
all outcomes were elevated 2- to 5-fold after the
occurrence of pneumonia, and, as in PARADIGM-HF,
the elevated risk remained significant after extensive
adjustment for other prognostic variables (Central
Illustration, Table 2). The adjusted HR for the risk of
death from any cause was 3.76 (95% CI: 3.09 to 4.58).
Sens i t iv i ty ana lyses . The excess risk observed in
each trial remained significantly elevated in the
sensitivity analyses. Therewas little attenuation of the
excess risk in the sensitivity analysis excluding epi-
sodes of pneumonia that coincided with a HF hospi-
talization; the number of those cases was 98 in
PARADIGM-HF (19% of pneumonia cases) and 77 in
PARAGON-HF (15% of pneumonia cases)
(Supplemental Table 1). There was somewhat more
attenuation in the analyses excluding patients who
died during an acute episode of pneumonia or those
who died during an episode of pneumonia or within
4weeks of suchanevent (Supplemental Tables 2 and 3).
TIME COURSE OF FATAL AND NONFATAL HF
OUTCOMES AFTER OCCURRENCE OF PNEUMONIA.
In both PARADIGM-HF and PARAGON-HF, the
elevated risk of all events examined was extremely
high in the first month following an episode of
pneumonia, remained elevated 2- to 4-fold from
months 1 to 3 and stabilized thereafter, with the
elevation in risk remaining 1.5- to 2-fold higher than
before the episode pneumonia (Tables 3 and 4,
Figures 1 and 2).
COMPARATOR GROUP (URINARY TRACT INFECTION).
Urinary tract infection was reported in 395 patients
(4.7%) in PARADIGM-HF and 579 patients (12.1%) in
PARAGON-HF, giving rates of 22 (95% CI: 20 to 24)
FIGURE 2 Risk of Clinical Outcomes After Occurrence of Pneumonia in PARAGON-HF
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Before Incident Pneumonia After Incident Pneumonia
The line graphs show the cumulative incidence risks of (A) the composite of the first HF hospitalization or CV death, (B) CV death, (C) the first HF hospitalization, and
(D) all-cause death after the occurrence of pneumonia. (E) The bar graph shows the incidence rates (per 100 patient-years) for the composite outcome of the first HF
hospitalization or CV death, CV death, HF hospitalization and all-cause death. The blue bars are the rates before the occurrence of pneumonia, and the red bars are the
rates after the occurrence of pneumonia. Abbreviations as in Figure 1.
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TABLE 3 Subsequent Risk of Clinical Outcomes Various Time Intervals After Occurrence
of Pneumonia in PARADIGM-HF
Unadjusted HR*
(95% CI) p Value
Adjusted HR*†
(95% CI) p Value
All-cause death
Within 1 month 21.69 (16.79–28.02) <0.001 17.78 (13.73–23.03) <0.001
>1 to 3 months 4.69 (3.38–6.51) <0.001 3.87 (2.78–5.38) <0.001
>3 months 2.68 (2.20–3.27) <0.001 2.21 (1.81–2.71) <0.001
CV death
Within 1 month 15.22 (10.88–21.28) <0.001 12.18 (8.69–17.08) <0.001
>1 to 3 months 3.11 (2.00–4.85) <0.001 2.54 (1.63–3.97) <0.001
>3 months 2.66 (2.13–3.33) <0.001 2.17 (1.73–2.72) <0.001
HF hospitalization
Within 1 month 10.34 (6.69–15.98) <0.001 8.32 (5.37–12.88) <0.001
>1 to 3 months 2.88 (1.70–4.89) <0.001 2.31 (1.36–3.92) 0.002
>3 months 1.62 (1.15–2.29) 0.006 1.31 (0.92–1.85) 0.13
CV death or
HF hospitalization
Within 1 month 11.62 (8.40–16.06) <0.001 9.48 (6.85–13.12) <0.001
>1 to 3 months 2.64 (1.73–4.03) <0.001 2.15 (1.41–3.28) <0.001
>3 months 1.96 (1.54–2.48) <0.001 1.59 (1.25–2.01) <0.001
*Hazard ratios were estimated with stratification by geographic region. †Adjusted variables included randomized
treatment, age, sex, left ventricular ejection fraction, NYHA functional class, systolic blood pressure, HF duration,
previous HF hospitalization, history of myocardial infarction, hypertension, diabetes, and atrial fibrillation, eGFR,
and log-transformed NT-proBNP.
Abbreviations as in Tables 1 and 2.
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1970and 45 (95% CI: 41 to 49) per 1,000 person-years,
respectively. The baseline characteristics of patients
who did or did not develop a urinary tract infection
are presented in Supplemental Table 4. Interestingly,
many of the variables associated with developing
pneumonia were also associated with higher risk of
urinary tract infection, including older age, longer
duration or more symptomatic HF, and more comor-
bidity (especially diabetes, but also chronic obstruc-
tive pulmonary disease); the one difference was sex,
with more women than men developing urinary
tract infection.
The subsequent risks of the primary composite
outcome and death (either cardiovascular or from any
cause) were higher after urinary tract infection, but
the elevation in risk was substantially less than with
pneumonia: Unadjusted HRs for the analyzed out-
comes ranged from 1.31 to 2.23, compared with 2.19 to
5.19 associated with pneumonia (Supplemental
Table 5).
EFFECT OF SACUBITRIL/VALSARTAN ON RISK OF
PNEUMONIA. Sacubitril/valsartan did not reduce the
risk of pneumonia in either trial. In PARADIGM-HF,
the HR for sacubitril/valsartan versus enalapril was
0.99 (95% CI: 0.83 to 1.17; p ¼ 0.88). In PARAGON-HF,
the HR for sacubitril/valsartan versus valsartan was
0.97 (95% CI: 0.81 to 1.15; p ¼ 0.69).DISCUSSION
We found that patients with both HFrEF and HFpEF
had a much higher incidence of pneumonia than is
usually reported in age- and sex-matched individuals
in the population. Patients developing pneumonia
were older and more comorbid than those not and the
occurrence of pneumonia was associated with sub-
stantially higher rates of fatal and nonfatal adverse
outcomes, even after adjustment for other prognostic
variables. The risk was greatest around the time of the
episode of pneumonia but remained elevated beyond
3 months after the event.
In adults in the general population, there is a
marked age dependency in the incidence of
community-acquired pneumonia. For example, in the
Cardiovascular Health Study, the rate of pneumonia in
participants aged 65 to 79 years was 10 per 1,000 per-
son-years (95% CI: 9 to 11 per 1,000 person-years),
rising steeply to 27 per 1,000 person-years (95% CI:
22 to 32 per 1,000 person-years) in those aged $80
years. In PARADIGM-HF (mean age 64 years) the
incidence of pneumonia was 29 per 1,000 person-years
(95% CI: 27 to 32 per 1,000-person years) and in
PARAGON-HF, where patients were on average about a
decade older (mean age 73 years), the incidence rate
was 39 per 1,000 person-years (95% CI: 36 to 42 per
1,000-person years). The higher than expected rates of
pneumonia are consistent with previous epidemio-
logic analyses, although those studies were unable to
specify HF phenotype (24–34). The reasons why pa-
tients with HF aremore susceptible to pneumonia than
other people are manifold and are both nonspecific
and specific in nature. Nonspecific predisposing fac-
tors include comorbidities such as chronic obstructive
pulmonary disease and chronic kidney disease and
other diverse contributors related to older age, ranging
from poor oral health through undernutrition to
reduced cell-mediated immunity. However, accumu-
lation of alveolar fluid may be a specific mechanism in
patients with HF, both impairing bacterial clearance
and disrupting the local defense against infection
(35,36). In keeping with this, we found that patients
who developed pneumonia generally exhibited more
symptoms and signs, and had higher NT-proBNP
levels, than those who did not develop pneumonia in
the 2 trials we studied.
Pneumonia was associated with an elevated sub-
sequent risk of all outcomes of interest. This was
especially true for mortality, with an overall 3- to 4-
fold higher risk of cardiovascular and all-cause death
after the occurrence of pneumonia. The risk of HF
hospitalization was also elevated, albeit not as much
TABLE 4 Subsequent Risk of Clinical Outcomes at Various Time Intervals After Incident
Pneumonia in PARAGON-HF
Unadjusted HR*
(95% CI) p Value
Adjusted HR*†
(95% CI) p Value
All-cause death
Within 1 month 36.34 (27.06–48.82) <0.001 31.29 (23.18–42.25) <0.001
>1 to 3 months 3.92 (2.44–6.29) <0.001 3.22 (2.00–5.18) <0.001
>3 months 2.19 (1.70–2.83) <0.001 1.79 (1.38–2.32) <0.001
CV death
Within 1 month 26.59 (17.48–40.44) <0.001 23.42 (15.30–35.84) <0.001
>1 to 3 months 3.98 (2.23–7.11) <0.001 3.26 (1.82–5.84) <0.001
>3 months 1.64 (1.13–2.37) 0.008 1.36 (0.94–1.97) 0.102
HF hospitalization
Within 1 month 8.18 (4.97–13.47) <0.001 7.39 (4.48–12.20) <0.001
>1 to 3 months 1.87 (0.93–3.77) 0.079 1.67 (0.83–3.36) 0.152
>3 months 1.64 (1.19–2.26) 0.002 1.47 (1.06–2.03) 0.022
CV death or
HF hospitalization
Within 1 month 11.56 (7.91–16.90) <0.001 10.50 (7.16–15.39) <0.001
>1 to 3 months 2.12 (1.20–3.76) 0.01 1.88 (1.06–3.33) 0.032
>3 months 1.56 (1.18–2.07) 0.002 1.40 (1.05–1.86) 0.024
*Hazard ratios were estimated with stratification by geographic region. †Adjusted variables included randomized
treatment, age, sex, left ventricular ejection fraction, NYHA functional class, systolic blood pressure, HF duration,
previous HF hospitalization, history of myocardial infarction, hypertension, diabetes, and atrial fibrillation, eGFR,
and log transformed NT-proBNP.
Abbreviations as in Tables 1 and 2.
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1971as the risk of death. The risk was also “front-loaded,”
with extremely high mortality rates in the first month
after an event with a steep decline in risk to around
3 months, after which it stabilized at 1.5- to 2.0-fold
higher than before the occurrence of pneumonia.
While it is tempting to attribute these raised risks to
the worse overall health profile of patients developing
pneumonia, along with severity of HF, they persisted
in multivariable analyses adjusting for an extensive
range of other prognostic factors. The finding of
continued elevation of risk beyond the acute episode
is also of interest given the observation in epidemio-
logic studies that acute pneumococcal infection ap-
pears to lead to a sustained subsequent elevation in
risk of myocardial infarction and stroke (1–3,37).
Persistence of systemic inflammatory and procoagu-
lant states are suggested mechanisms explaining this
observation and organ injury (e.g., kidney and
myocardial injury) at the time of acute infection may
also have longer term consequences (37–39).
Although our findings show only an association
between pneumonia and worse outcomes and do not
prove cause and effect, there seems little doubt that
prevention of pneumonia is important in patients
with HF. The most common pathogen causing pneu-
monia is Streptococcus pneumoniae, for which 2 vac-
cines are available (12,40). Although pneumonia (and
influenza) vaccination is advocated for older adults in
the general population and in all major HF guidelines,
it is consistently found to be underutilized. In a
recent review, the estimated vaccination coverage in
immunocompetent adults $65 years in the USA was
only 47%, and similarly low levels have been reported
in European countries with a national health service
(5,10). Although higher in a large U.S. heart failure
registry, pneumococcal vaccination rates were re-
ported to have decreased from 71% in 2013 to 60% in
2016 (13). This missed opportunity may be relatively
more important in patients with HFpEF, given their
older average age, higher rate of pneumonia, and
absence of other treatment options.
As with any study of this type, there are limita-
tions. The analyses were retrospective and had not
been prespecified. The patients included in both trials
were selected and likely less comorbid than in the
“real world.” Cases of pneumonia were reported by
investigators as serious adverse events and were not
adjudicated, and it is possible that different criteria
for pneumonia diagnosis may have been used by
different investigators, although any hospitalization
with any feature raising a possibility of worsening HF
was reported. The lack of effect of sacubitril/valsartan
on these events suggests that they were not missed
HF events. Our approach to pneumonia definitionwas also at least as robust as used in epidemiologic
and registry studies, and the rates of pneumonia that
we observed are consistent with those expected in an
older high-risk population (5,40). We had no infor-
mation on the specific cause of pneumonia (38).
CONCLUSIONS
We found that incidence of investigator-reported
pneumonia was high in patients with HF, especially
HFpEF. An episode of pneumonia was of considerable
prognostic importance, as it was associated with an
approximately 4-fold elevation in risk of death.
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COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Pneumonia is common in
patients with either HFrEF or HFpEF and is associated
with high short-term mortality and worse longer-term
outcomes.
TRANSLATIONAL OUTLOOK: The mechanisms un-
derlying the sustained risk after pneumonia warrant
further investigation and more aggressive use of pneu-
mococcal and influenza vaccinations is encouraged in
patients with heart failure.
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